Skip to main content

Table 5 OS according to clinicophathological characteristics

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

  Mean OS (95% CI)a (months) p-value
Overall 9.2 (5.3–13.2)  
Age (years)
≤ 70 6.1 (0.3–11.8) 0.27
> 70 10.0 (7.2–12.8)
Gender
Male 8.9 (5.1–12.8) 0.76
Female 9.2 (2.3–16.1)
Histology
Adenocarcinoma 9.2 (4.6–13.9) 0.56
Squamous 9.8 (2.5–17.2)
PS ECOG
0 9.2 (5.6–12.8) 0.65
> 1 2.0 (0.1–5.4)
Smoke
Never smoker 9.9 (0.1–20.5) 0.80
Smoker 8.9 (4.7–13.2)
Prior treatment lines, n
1 6.1 (3.6–8.5) 0.036
≥ 2 12.2 (8.2–13.3)
RECIST response
No response 6.4 (4.8–8.0) < 0.001
Response 13.5 (11.2–15.7)
  1. aMedian survival not reached